Syndax Pharmaceuticals Inc (SNDX) saw an uptrend of 2856137% in the recent trading with $2190000.0 being its most recent. The current price level -63.22% lower than the highest price of $25.07 marked by the stock while trading over the past 52-weeks, whereas it is 7.46% higher than the lowest price of $8.58 the company dropped to over past 52-weeks. The latest news story on SNDX appeared in (GlobeNewswire) under the title “Syndax Announces FDA Priority Review of sNDA for Revuforj (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia” on Today.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.25 for the stock.
Syndax Pharmaceuticals Inc Earnings – What Happened With SNDX
Coming around sales and income figures on SNDX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Syndax Pharmaceuticals Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 86.05 million. SNDX does have institutional investors; and they hold 116.11% of the stock.
As on 2024-06-30, BLACKROCK INC. was the top most holder in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) with an ownership of 7.91 million shares of the company or 9.2721 of the stake worth $162.33 million. The filing also reveals WELLINGTON MANAGEMENT GROUP LLP as the second largest holder in the company with a control over 8.6063 of the outstanding shares. Its stake is worth $150.67 million for having 7.34 million shares in hand.
KYNAM CAPITAL MANAGEMENT, LP also came holding a key position in the company during the recent quarter and it now holds 6.7101 of the outstanding shares. With this there are now 299.0 institutions which have possession in SNDX’s shares.
Key Metrics forSNDX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Syndax Pharmaceuticals Inc has a debt to equity ratio of 1.61.
Technical Analysis of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Syndax Pharmaceuticals Inc (SNDX), we notice that the stock’s 20-day average volume is at 1,734,610 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 2,248,434 shares. And to end, SNDX’s 100-day average volume is 2,223,095 shares with 100% of the long-term indicators pointing towards Sell for the stock.
